ResearchIsomorphic LabsConfirmed
Story 11 of 18 in the Tuesday 17 November editionIsomorphic Labs raises $5B Series C to scale its AI drug design engine
Co-led on 17 November 2026 by Greenoaks and Sequoia Capital with Andreessen Horowitz, Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.
Alphabet spin-out Isomorphic Labs and founder Demis Hassabis announced on 17 November 2026 that the London AI drug discovery company has raised $5 billion in Series C funding co-led by Greenoaks and Sequoia Capital alongside Andreessen Horowitz, Alphabet and all existing investors to scale its Isomorphic Labs Drug Design Engine (IsoDDE) and advance internal therapeutic candidates towards clinical trials.
Study details
- Financing round and size
- $5 billion Series C announced on 17 November 2026 (post-money valuation undisclosed)
- Co-lead and new investors
- Co-led by Greenoaks and Sequoia Capital, joined by Andreessen Horowitz (a16z) and Alphabet
- Returning investors
- Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund
Release details & context
Scaling IsoDDE beyond AlphaFold 3 towards internal clinical programmes
Founded out of Alphabet in London, Isomorphic Labs centres its research on the proprietary Isomorphic Labs Drug Design Engine (IsoDDE), combining predictive and generative models that extend beyond AlphaFold 3 biomolecular structure prediction to map chemical space from first principles alongside research Collaborations such as Johnson & Johnson.
Sources
- PrimaryIsomorphic Labs announces Series C investment roundisomorphiclabs.com
- On XDemis Hassabis (@demishassabis) $5B funding announcement on Xx.com
Related research launches
- OpenAI launches science blog with GPT-6 Astra Standard Model proof
OpenAI debuts its science blog with UCSB physicist Nathaniel Craig’s candidate nonperturbative Standard Model lattice proof built with GPT-6 Astra.
- OpenAI expands ChatGPT for Academic Researchers to 200,000 scientists
OpenAI opens 50,000 ChatGPT for Academic Researchers grants on 23 November for up to 200,000 scientists, reporting 1.9 times faster work.
- OpenAI cuts AMD GPU PPA up to 14% and partners on GPT-Synopsys
OpenAI details up to 14% power, performance and area gains on AMD flagship GPU IP sent to manufacturing and announces GPT-Synopsys with Synopsys.
- OpenAI reports $2,400 daily median researcher agent spend in RSI study
OpenAI’s Jagged Frontier report logs $2,400 median daily researcher agent spend, 5.7 agent workdays per day and 77% Safety workweek growth.

